Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I got 400k.. that's all i got.
no fill onj my 1mm buy at ask.. been there 20 min
Big MRNA news >> MDRNA, Inc. Acquires Cequent Pharmaceuticals
BOTHELL, WA and CAMBRIDGE, MA -- (Marketwire)
04/01/10
MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, and Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based therapeutics, announced today the signing of a definitive agreement pursuant to which MDRNA will acquire Cequent in an all stock transaction valued at approximately $46 million. The combined company will have multiple proprietary RNAi drug discovery platforms with the capability to deliver RNAi-based therapeutics via systemic, local and oral administration. In addition, the acquisition expands MDRNA's oncology pipeline with a product for Familial Adenomatous Polyposis (FAP) -- a genetic disorder that is a precursor to colon cancer -- that will soon begin Phase 1 clinical testing under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). The transaction will include certain loan provisions that will fund MDRNA operations through the anticipated closing of the merger in early July 2010.
"We anticipate that this transaction will accelerate the development of the most promising products of both companies," commented Mr. Bruce Thaw, Esq., Chairman of the Board of MDRNA. "We believe that the combined company will be in a strong position to advance multiple RNAi drug discovery platforms, establish premier R&D partnerships with large pharmaceutical and biotechnology companies and accelerate RNAi-based therapeutics to patients in need."
The combined company will be headquartered in Bothell, Washington with offices in Cambridge, Massachusetts. RNAi drug discovery, research and biology will continue to be conducted at MDRNA's state-of-the-art R&D facility in Bothell while clinical operations will reside in Cambridge. The combined company will leverage resources and its proven management team to further advance MDRNA's proprietary UsiRNA construct and DiLA2 delivery technologies as well as Cequent's TransKingdom RNAi technology to develop novel RNAi-based therapeutics. In addition, Cequent will have certain cash amounts on hand at the close of the acquisition which will fund the combined operations into December 2010.
"The combined company will have a unique set of complementary capabilities, skills and clinical programs," stated J. Michael French, President & CEO of MDRNA. "With a world-class research, development and clinical team, a broad intellectual property estate and a clinical pipeline, we believe the combined company will emerge as one of the preeminent leaders in the RNAi sector. We are very excited to bring to MDRNA the unparalleled expertise and commitment of the Cequent team."
Mr. French will serve as the President, CEO and board member of the combined entity. Peter D. Parker, Cequent's President and CEO will assume the Chairmanship of the combined company's Board of Directors. The new Board of Directors will include an additional five members, two each from the existing boards of MDRNA and Cequent, and one additional independent director to be chosen by the new combined Board.
"This transaction is a great fit for Cequent," stated Peter D. Parker, President and CEO of Cequent Pharmaceuticals. "We were seeking access to a world class RNAi research team, and MDRNA was looking for strong development, regulatory and clinical management expertise. For our venture capital backers, who include Ampersand, Novartis and Pappas Ventures, this natural evolution of their investment will allow us to reach the next level of success."
About the Combined Company
The combined company will leverage the following relationships, assets and opportunities to accelerate revenue generation and product development:
Two validated RNAi Drug Discovery Platforms (MDRNA's UsiRNA/DiLA2 platform and Cequent's TransKingdom RNAi platform) which utilize two distinct and proprietary delivery technologies for systemic, local and oral delivery.
Oncology and inflammatory disease pipeline:
One accepted IND in FAP and Phase 1 Clinical Trial expected in 2Q2010.
Three additional INDs projected by 2Q2011:
Bladder Cancer;
Inflammatory Bowel Disease (IBD); and
AXL / fitb did 1000% in 12 months ;)
madoff.. you are swinging this.. sold b4 for .10?? nice.. could had a double.. we are approaching. Anyways.. I'm sure you'd like to inspire hesitancy in holding so you can buy another dip and sell it.
I have no problem w/ that... but no need make veiled assersions here. Thanks though.. at least I know your M/O.. and so should this board.
-Hero
Yes, I agree it is the guidance or expectation there of.. this is why there are no sellers. Next few Q's we jump an order of magnitude.
-Hero
Alert MMRF. No one is selling here.
yea.. that .195 on the ask will be here soon. No one is selling here. gee whadda surprise!
Stock of 2010 = MMRF. DD it.. chart it etc. This is a lifechanger stock.. not a day trade. They have the right product at historical times. Much dd on their board.
Look at their latest news and earnings and cc / 2day.
-Hero
Cardium Reports On Recent Norwegian Study Revealing That History Of Foot Ulcers Is A Significant Predictor Of Mortality In Diabetic Patients
http://discusspharmacy.com/2010/03/cardium-reports-on-recent-norwegian-study-revealing-that-history-of-foot-ulcers-is-a-significant-predictor-of-mortality-in-diabetic-patients/
-Hero
This is a potentially life changing event. I want to hear forcasted numbers from the recent agreement. Believe me.. no one knows about this yet. Digitizing and recording everyone's health profile / history will become par.
I'm telling you.. this is going to be huge. I am looking out 1-2 years. This is a retirement stock.. for even 10 grand right here. I could care less about dime fluctuations from this level.
-Hero
SLPO folks.. watch the chart here :)
not in yet.. but I want to see if they try to fill that gap @ .127
They tried yesterday.. but I know i came in heavy yesterday @ .14.. and got most of them.. then .15 and .16 lol I found this late.. so I have no sub .12's :(
I did quite a bit of dd here.. and man this is truly a diamond among the rocks. I am not trading this. This will be $1+ by year end or next year. I have more coin on friday.. so I won't mind to see any mega dips here. I remember.. AXL .50 to $10 currently / FITB from 1.30 to $13+ currently.. both happened in last 12 months.
Does anyone really believe this will be in pennies 12 months from now?? Not me, sir.
-Hero
don't support .15.. we may be able to get it lower. Have 200k here.. and I'd like some more for my IRA.
-Hero
Alert: MMRF DD this one... dirt cheap prices w/ everything that's going on w/ this company.
disclosure: 200k shares
I want to see nother dip to .14 on ask :) c'mon mm's. I know u can do it.
This is a long term investment.. so not worried bout fast rises. They are in the right sector at historic times. Load all you can in the teens..
Someone please ask if ceo can put a 12-18 month number on the recent agreement. That would set this on pace towards a buck. IMO
get MMRF b4 close. Huge news!! cc in morn
MMRF finally moving off news
A close > .15 is VERY bullish..
in WPCS w/ 2k shares. Thanks for the heads up.
-Hero
When is conf call? link to listen tia
Clay.. is time to do another MMRF chart?? pls/?? thank in advance
-Hero
MMRF - news is huge. resistance .15.. then .20.. then blue skies. cc on wed.
-Hero
Just found MMRF. Luv that news. They are in the right sector at historical times.
Accumulated 100k 2day. Glad to be here. Looking forward to Wed's cc
-Hero
In CXM yesterday @ .50. 4X volume yesterday told the story.
tic-toc tic-tic.. toc :)
Looks like we'll break that .52 on the open. Nice to get in b4 the news or momo players. Excellerate 510k can be any day or hour.
-Hero
I really like CXM this week for 510k approval of Excellerate. 4X volume out of no where.
disclosure: In @ .50. I'll buy more on any nice dip 2day.
GLTU
In CXM. 510k approval any day for Excellerate. Completed direct offering. 2 drugs going into phase III. Chart is great. psar flipped pos. 4X volume.
-Hero
In CXM. 510k approval anytime now. .52 pivot about to be breached. 4X volume yesterday.
-Hero
In CXM here. FDA approval could come any minute / hour day.
Man, that .002 is a strong base... 50%+ increase from here tomorrow. :)
Agreed.. couple weeks, folks are gonna wish they bought in the .002's & .003's.
the whole week IMO. .003's for sure 2morrow. 20 MA = .004 hehe
Dats where we headed :)
Agreed! In for 7MM.. and won't sell any til .005' are hit.
those dips i added @ are up 50% already LOL We bust .002's here b4 lunch IMO
I know mc.. I am just pointing out that the chart has broken down.. whethyer contrived or not.. it makes a difference to chartists coming in here and adding needed volume.
That's all i'm saying.
-Hero
Added AFYG 2day @ .30. Hard fill.
mc - they need news. CYRS broke import support on the chart. So, will c some selling here until bid firms up.